Cargando…

Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours

Overactivation of the mitogen-activated protein kinase (MAPK) pathway is an important driver of many human cancers. First line, FDA-approved therapies targeting MAPK signalling, which include BRAF and MEK inhibitors, have variable success across cancers, and a significant number of patients quickly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paton, Emily L., Turner, Jacqueline A., Schlaepfer, Isabel R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199609/ https://www.ncbi.nlm.nih.gov/pubmed/32411231 http://dx.doi.org/10.1155/2020/1079827

Ejemplares similares

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations
por: Obaid, Nourah Mohammad, et al.
Publicado: (2017)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways
por: Jain, Payal, et al.
Publicado: (2017)

BRAF Modulates Lipid Use and Accumulation
por: Turner, Jacqueline A., et al.
Publicado: (2022)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
por: Chan, Xian Yang, et al.
Publicado: (2017)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease
por: Cronin, Christopher, et al.
Publicado: (2022)

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations
por: Lu, Meng-Di, et al.
Publicado: (2022)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
por: Azimi, Alireza, et al.
Publicado: (2018)

BRAF Mutations and Resistance of Non-Small Cell Lung Cancer to BRAF-Targeted Therapies Using Liquid Biopsy
por: Li, Ming, et al.
Publicado: (2021)

In search of effective therapies to overcome resistance to Temozolomide in brain tumours
por: Bouzinab, Kaouthar, et al.
Publicado: (2019)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors
por: Mulcahy Levy, Jean M, et al.
Publicado: (2017)

Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
por: Pópulo, Helena, et al.
Publicado: (2021)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

SPDR-1 HSP90 inhibition overcomes resistant to molecular targeted therapy in BRAF(V600E) mutant glioblastoma
por: Sasame, Jo, et al.
Publicado: (2021)

HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E
por: Chang, Xiaoyu, et al.
Publicado: (2020)

Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors
por: Lee, Kye Hwa, et al.
Publicado: (2020)

Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations
por: Ahronian, Leanne G., et al.
Publicado: (2015)

Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
por: Reger de Moura, Coralie, et al.
Publicado: (2019)

The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors
por: Delmas, Audrey, et al.
Publicado: (2015)

Discoidin Domain Receptors in Melanoma: Potential Therapeutic Targets to Overcome MAPK Inhibitor Resistance
por: Reger de Moura, Coralie, et al.
Publicado: (2020)

Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS
por: Zuidervaart, W, et al.
Publicado: (2005)

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E)
por: Antonello, Zeus A., et al.
Publicado: (2017)

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC
por: Yeh, Jen-Hao, et al.
Publicado: (2021)

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
por: Goldinger, Simone M., et al.
Publicado: (2013)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells
por: Fisher, Matthew L., et al.
Publicado: (2017)

Targeting hypoxic tumour cells to overcome metastasis
por: Bennewith, Kevin L, et al.
Publicado: (2011)

BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge
por: Florent, Laetitia, et al.
Publicado: (2023)

Targeting BRAF-mutant tumours with TGFBR1 inhibitors
por: Spender, Lindsay C, et al.
Publicado: (2017)

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer
por: Pickles, Oliver J., et al.
Publicado: (2020)

Overcoming resistance to BRAF(V600E) inhibition in melanoma by deciphering and targeting personalized protein network alterations
por: Vasudevan, S., et al.
Publicado: (2021)

BIOL-05. MAPK PATHWAY INHIBITION SENSITIZES TO IMMUNOTHERAPY IN BRAF-MUTANT GLIOMAS
por: Park, Jong-Whi, et al.
Publicado: (2021)

Evolution of resistance to MAPK-targeted therapies
por: Lo, Roger
Publicado: (2015)

Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance
por: Nguyen, Ngoc Minh, et al.
Publicado: (2022)

Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy
por: D’Amico, Silvia, et al.
Publicado: (2022)

A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy
por: Banerjee, Natasha, et al.
Publicado: (2016)

Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib
por: Kian, Waleed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q7tqt1h6liub4a3i40fc92g2j8